Abstract
Cardiorenal syndrome (CRS) is a condition in which there is a complex interrelationship between cardiovascular disease (CVD) and chronic kidney disease (CKD). Impairment of one organ could accelerate pathological processes in the other, which in turn accelerates the progression of failure of both. Although clinical studies hint at a specific bidirectional interaction between cardiovascular system and kidney, insight into the pathogenesis of CRS remains unknown. One possible factor that could explain this link is endothelial dysfunction (ED). ED is not only involved in initiation and progression of atherosclerosis, but also contributes to progression of renal injury. Asymmetric dimethylarginine (ADMA) is an endogenous NO synthase inhibitor found in the plasma and cells. Plasma ADMA levels are increased in CKD patients and known to be an independent biomarker and predictor for future cardiovascular events as well as the progression of CKD. These findings indicate that accumulated ADMA-mediated ED may play important roles in CRS in CKD patients. In this review, we discuss the roles of ADMA in the development of ED, especially focusing on its roles in CRS.
Keywords: Asymmetric dimethylarginine, CVD, CKD, dimethylarginine dimethylaminohydrolase, endothelial dysfunction, nitric oxide.
Current Pharmaceutical Design
Title:Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome
Volume: 20 Issue: 14
Author(s): Seiji Ueda, Sho-ichi Yamagishi, Miyuki Yokoro and Seiya Okuda
Affiliation:
Keywords: Asymmetric dimethylarginine, CVD, CKD, dimethylarginine dimethylaminohydrolase, endothelial dysfunction, nitric oxide.
Abstract: Cardiorenal syndrome (CRS) is a condition in which there is a complex interrelationship between cardiovascular disease (CVD) and chronic kidney disease (CKD). Impairment of one organ could accelerate pathological processes in the other, which in turn accelerates the progression of failure of both. Although clinical studies hint at a specific bidirectional interaction between cardiovascular system and kidney, insight into the pathogenesis of CRS remains unknown. One possible factor that could explain this link is endothelial dysfunction (ED). ED is not only involved in initiation and progression of atherosclerosis, but also contributes to progression of renal injury. Asymmetric dimethylarginine (ADMA) is an endogenous NO synthase inhibitor found in the plasma and cells. Plasma ADMA levels are increased in CKD patients and known to be an independent biomarker and predictor for future cardiovascular events as well as the progression of CKD. These findings indicate that accumulated ADMA-mediated ED may play important roles in CRS in CKD patients. In this review, we discuss the roles of ADMA in the development of ED, especially focusing on its roles in CRS.
Export Options
About this article
Cite this article as:
Ueda Seiji, Yamagishi Sho-ichi, Yokoro Miyuki and Okuda Seiya, Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113199990480
DOI https://dx.doi.org/10.2174/13816128113199990480 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insulin Therapy in Pregnancy Hypertensive Diseases and its Effect on the Offspring and Mother Later in Life
Current Vascular Pharmacology Aged Garlic Extract Consumption Causes Significant Increases in Plasma Nitric Oxide Synthase Activity and Nitric Oxide Levels in Atherosclerotic Patients
Vascular Disease Prevention (Discontinued) Oral Chemotherapy in Elderly Women with Metastatic Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Pathophysiology of Post-Operative Low Cardiac Output Syndrome
Current Vascular Pharmacology Cardiac Toxicities of Antiangiogenic Therapies
Current Angiogenesis (Discontinued) Free Fatty Acids: Circulating Contributors of Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Estimation of Familial Combined Hyperlipoproteinemia Prevalence in a Large Rural Population: The Brisighella Heart Study
Vascular Disease Prevention (Discontinued) Nanomedicine for Intranasal Delivery to Improve Brain Uptake
Current Drug Delivery Review of Olmesartan Medoxomil in Achieving Guideline-Recommended Target BP Goals and Implications for Managed Care
Current Hypertension Reviews RAAS Inhibition and Renal Protection
Current Pharmaceutical Design Potential Mechanisms of Failure in the Sudden Infant Death Syndrome
Current Pediatric Reviews Effects of Endothelins on Cardiac and Vascular Cells: New Therapeutic Target for the Future?
Current Vascular Pharmacology The Role of Oxidative Stress in the Pathogenesis of Type 2 Diabetes Mellitus Micro- and Macrovascular Complications: Avenues for a Mechanistic-Based Therapeutic Approach
Current Diabetes Reviews Asymmetric Dimethylarginine: a Key Player in the Pathophysiology of Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis in Rheumatoid Arthritis?
Current Pharmaceutical Design Microcirculation Dysfunction: A Possible Mechanism Responsible for Reverse Redistribution in Myocardial Perfusion Imaging?
Current Medical Imaging Graphical Abstracts
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Diabetes and Gestational Hypertension
Current Hypertension Reviews Radiation-Induced Extracranial Carotid Stenosis
Vascular Disease Prevention (Discontinued) Is There An Association Between Vitamin D and Hypertension?
Recent Patents on Cardiovascular Drug Discovery Carotid Ultrasound in One, Two and Three Dimensions
Vascular Disease Prevention (Discontinued)